GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex

CAR-T Digest - August 2020

14 Nov 2024: GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex

GSK is focusing on Blenrep (belantamab mafodotin) for second-line multiple myeloma treatment, projecting significant market potential for the antibody-drug conjugate
New data from the Phase III DREAMM-7 study show better survival outcomes for Blenrep compared to Johnson & Johnson’s Darzalex (daratumumab), with a 60% greater reduction in the risk of death or disease progression
Follow-up data from DREAMM-7 indicate a statistically significant reduction in death risk for patients treated with Blenrep, with further results to be presented at the 2024 American Society of Hematology Annual Meeting
The European Medicines Agency has accepted GSK’s marketing authorization application for Blenrep in combination with bortezomib and dexamethasone or pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
Blenrep targets the BCMA protein on multiple myeloma cells and uses a microtubule inhibitor payload to induce cell death, although it was previously withdrawn from the market after failing a confirmatory trial in November 2022